CN116607266A - Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof - Google Patents
Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof Download PDFInfo
- Publication number
- CN116607266A CN116607266A CN202310588938.9A CN202310588938A CN116607266A CN 116607266 A CN116607266 A CN 116607266A CN 202310588938 A CN202310588938 A CN 202310588938A CN 116607266 A CN116607266 A CN 116607266A
- Authority
- CN
- China
- Prior art keywords
- giant salamander
- gelatin
- nanofiber membrane
- polylactic acid
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002121 nanofiber Substances 0.000 title claims abstract description 74
- 241000157862 Dicamptodontidae Species 0.000 title claims abstract description 70
- 239000012528 membrane Substances 0.000 title claims abstract description 62
- 230000028327 secretion Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 108010010803 Gelatin Proteins 0.000 claims abstract description 55
- 239000008273 gelatin Substances 0.000 claims abstract description 55
- 229920000159 gelatin Polymers 0.000 claims abstract description 55
- 235000019322 gelatine Nutrition 0.000 claims abstract description 55
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 55
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 42
- 239000004626 polylactic acid Substances 0.000 claims abstract description 42
- 238000009987 spinning Methods 0.000 claims abstract description 31
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000007731 hot pressing Methods 0.000 claims abstract description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001523 electrospinning Methods 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 8
- 238000001816 cooling Methods 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 33
- 208000027418 Wounds and injury Diseases 0.000 description 26
- 206010052428 Wound Diseases 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010050062 mutacin GS-5 Proteins 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/58—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products
- D01F6/62—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters
- D01F6/625—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters derived from hydroxy-carboxylic acids, e.g. lactones
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43838—Ultrafine fibres, e.g. microfibres
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/54—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving
- D04H1/558—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving in combination with mechanical or physical treatments other than embossing
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/54—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving
- D04H1/559—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving the fibres being within layered webs
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/12—Aldehydes; Ketones
- D06M13/123—Polyaldehydes; Polyketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/02—Natural fibres, other than mineral fibres
- D06M2101/10—Animal fibres
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/32—Polyesters
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Botany (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to the technical field of medical dressing, and provides an asymmetric nanofiber membrane containing giant salamander skin secretion, and a preparation method and application thereof. According to the invention, polylactic acid electrostatic spinning solution and gelatin giant salamander mixed spinning solution are respectively subjected to electrostatic spinning to prepare polylactic acid nanofiber membranes and gelatin giant salamander mixed nanofiber membranes, a part of gelatin giant salamander mixed nanofiber membranes are crosslinked, and the gelatin giant salamander mixed nanofiber membranes, the crosslinked gelatin giant salamander mixed nanofiber membranes and the polylactic acid nanofiber membranes are sequentially subjected to hot pressing in a superimposed manner, so that the asymmetric nanofiber membrane containing skin secretion of the giant salamander is obtained. The asymmetric nanofiber membrane dressing provided by the invention can be automatically adhered to the surface of a wound to repair the wound, the wound can be removed from the surface of the skin after extremely short-time cooling is performed on the surface of the dressing, and painless dressing replacement can be realized while pain of the wound of a patient is relieved in a short cooling process.
Description
Technical Field
The invention relates to the technical field of medical dressings, in particular to an asymmetric nanofiber membrane containing giant salamander skin secretion, and a preparation method and application thereof.
Background
Skin defects are common injuries in daily life work, and not only need to stop bleeding in time, but also need to recover the functions of regenerated tissues. This places greater demands and challenges on current wound dressings. The ideal wound dressing should possess excellent overall properties. Firstly, the dressing should be soft and adaptable, create a moist environment at the skin window and isolate the wound from the external adverse environment, so as to promote wound repair and prevent secondary injury or bacterial infection of the wound. In addition, the dressing should have good cell compatibility to promote cell proliferation and cell migration processes.
In recent years, some new wound dressings have been designed and proposed, such as hydrogels, cellulose sponges, nanofibers, and the like. Among these new wound dressings, nanofibers produced by electrospinning have attracted considerable attention. Compared with the traditional fiber, the nanofiber has smaller, softer and larger specific surface area, and better air permeability is also a great advantage of the nanofiber dressing.
To solve the problems associated with the use of surgical sutures, or the problem of simple wound repair procedures in which the dressing can be adhered directly to the wound surface without external fixation, materials have been developed to date that have very strong adhesive properties, mainly adhesives in the form of hydrogels, that provide better mechanical properties and good biological properties than commercial adhesives used in clinical applications while having a certain adhesion. However, to avoid pain during dressing changes and to maximize the protection of the wound from secondary injury, a clinical problem still exists today with painless changes to the wound dressing.
Disclosure of Invention
The invention aims to provide an asymmetric nanofiber membrane containing giant salamander skin secretion, and a preparation method and application thereof, so that a dressing film can be easily attached to a wound, the in-vivo tissue regeneration process can be accelerated, and meanwhile, no unnecessary reaction can be caused in the wound repair process. Painless replacement is also achieved.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a preparation method of an asymmetric nanofiber membrane containing giant salamander skin secretion, which comprises the following steps:
(1) Preparing a polylactic acid electrostatic spinning solution and a gelatin giant salamander mixed spinning solution;
(2) Respectively carrying out electrostatic spinning on the polylactic acid electrostatic spinning solution and the gelatin giant salamander mixed spinning solution to prepare a polylactic acid nanofiber membrane and a gelatin giant salamander mixed nanofiber membrane;
(3) Crosslinking a part of gelatin giant salamander mixed nanofiber membrane to obtain a crosslinked gelatin giant salamander mixed nanofiber membrane;
(4) And sequentially superposing and hot-pressing the gelatin giant salamander mixed nanofiber membrane, the crosslinked gelatin giant salamander mixed nanofiber membrane and the polylactic acid nanofiber membrane to obtain the asymmetric nanofiber membrane containing skin secretion of the giant salamander.
Preferably, the preparation method of the polylactic acid electrostatic spinning solution in the step (1) comprises the following steps: dissolving polylactic acid in V Chloroform (chloroform) :V Dimethylformamide =6 to 8: and 2-4 to obtain the polylactic acid electrostatic spinning solution with the mass concentration of 5-15%.
Preferably, the gelatin giant salamander mixed spinning solution in the step (1) is: dissolving giant salamander skin secretion in a gelatin glacial acetic acid solution with the mass volume concentration of 15-25% to obtain a gelatin giant salamander mixed spinning solution with the volume concentration of 1-5%.
Preferably, in the step (2), the electrostatic spinning adopts a 12-18 mL injector to push spinning solution, the voltage is 50-70 kv, the solution flow rate is 0.8-2 mL/h, the needle receiver is non-woven fabric, the distance between the needle tip of the injector and the receiver is 15-19 cm, the indoor temperature is 22-28 ℃, the relative humidity is 40-60%, and the spinning time is 20-30 min.
Preferably, the diameter of the polylactic acid nanofiber membrane and the gelatin giant salamander mixed nanofiber membrane is 345-405 nm.
Preferably, the crosslinking in step (3) is performed using glutaraldehyde solution: the volume concentration of the glutaraldehyde solution is 45-55%; .
Preferably, the temperature of the hot pressing is 90-110 ℃; the pressure of the hot pressing is 0.4-0.6 MPa.
The invention provides an asymmetric nanofiber membrane containing giant salamander skin secretion.
The invention provides an application of an asymmetric nanofiber membrane containing giant salamander skin secretion as a wound dressing.
According to the invention, the polylactic acid electrostatic spinning solution is prepared, and the gelatin giant salamander mixed spinning solution is prepared; respectively carrying out electrostatic spinning on the polylactic acid electrostatic spinning solution and the gelatin giant salamander mixed spinning solution to prepare a polylactic acid nanofiber membrane and a gelatin giant salamander mixed nanofiber membrane, crosslinking part of the gelatin giant salamander mixed nanofiber membrane, sequentially superposing and hot-pressing the gelatin giant salamander mixed nanofiber membrane, the crosslinked gelatin giant salamander mixed nanofiber membrane and the polylactic acid nanofiber membrane, and obtaining the asymmetric nanofiber membrane containing skin secretion of the giant salamander.
The asymmetric nanofiber membrane dressing provided by the invention can be automatically adhered to the surface of a wound to repair the wound, so that the regeneration process of in-vivo tissues is accelerated, and any unnecessary reaction is not caused. After the wound repair is completed, the gelatin giant salamander mixed nanofiber membrane layer is gradually decomposed on the applied surface, so that no trace is left on the tissue micro-morphology, the tissue micro-morphology is not changed, the gelatin giant salamander mixed nanofiber membrane layer can be taken down from the skin surface after extremely short-time cooling is performed on the dressing surface, and the painless dressing replacement can be realized while the pain of the wound of a patient is relieved in a short cooling process.
The invention utilizes the electrostatic spinning method, and the prepared polylactic acid nanofiber outer layer can isolate external water from penetrating to prevent wound pollution and bacterial breeding. The inner layer has strong adhesiveness, can be attached to the surface of a wound, has the functions of stopping bleeding, resisting bacteria and the like, and promotes the wound to heal quickly. Gelatin, giant salamander powder and polylactic acid used for the nanofiber dressing are all derived from natural animals and plants, have good biocompatibility and degradability, and are environment-friendly dressing. The dressing simultaneously satisfies the functions of coagulation, antibiosis and antiphlogosis and promotes tissue repair, the nanofiber dressing is easy to operate, reasonable in structural design, mature and easy to operate in manufacturing process, can still maintain good mechanical properties under the condition of different moisture contents, can be widely applied to dynamic wound management of joints and the like to complete related tasks of skin wound treatment, does not need to be fixed by supporting materials, and has good application prospects.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only embodiments of the present invention, and that other drawings can be obtained according to the provided drawings without inventive effort for a person skilled in the art.
FIG. 1 is a scanning electron microscope image of a gelatin giant salamander mixed fiber membrane prepared by using a gelatin giant salamander mixed spinning solution containing skin secretions of giant salamander with different concentrations under different spinning voltages in the embodiment 1 of the invention;
FIG. 2 is a schematic illustration of a thermal compression process for the asymmetric nanofiber membrane dressing of example 2;
FIG. 3 is a graph showing the results of mechanical property testing of different nanofiber membranes according to example 3 of the present invention;
FIG. 4 is a graph showing the results of the adhesion performance test of PGSGS in example 4 of the present invention;
FIG. 5 is a graph showing the contact angle performance test results of PLA, GS, and GS (c) in example 5 of the present invention;
FIG. 6 is a statistical chart of cytotoxicity test results of gelatin, GS (c) and PLA in example 6 of the present invention;
FIG. 7 is a live/dead status chart of cells co-cultured with dressing taken from the confocal of GS and PGSGS in example 6 of the present invention.
Detailed Description
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
And preparing gelatin giant salamander mixed spinning solution with the skin secretion concentration of 0%, 1%, 3%, 5% and 7%. Specific: and dissolving skin secretion of the giant salamander in the proportion into gelatin glacial acetic acid solution with the mass volume concentration of 20%, and heating and magnetically stirring for 5 hours at 50 ℃ to obtain gelatin giant salamander mixed spinning solution with the concentration.
And (3) adopting a 15ml syringe to push the spinning solution for electrostatic spinning to prepare the gelatin giant salamander mixed nanofiber membrane (GS). When spinning is carried out on the gelatin giant salamander mixed spinning solution, three voltages (50, 60 and 70 kv) are respectively adopted for spinning the five spinning solutions. Other spinning conditions were unchanged. The flow rate of the solution is 1mL/h, the receiver is non-woven fabric, the distance between the needle tip of the injector and the receiver is 17cm, the indoor temperature is 25 ℃, the relative humidity is 50%, and the spinning time is 30min.
And observing the physical appearance of the gelatin giant salamander mixed nanofiber membrane/nanofiber wound dressing prepared by different giant salamander secretion concentrations according to different spinning voltages by adopting a scanning electron microscope (SEM, HITACHI-8010, japan), wherein the acceleration voltage is set to be 5kV. Before the scanning electron microscope scanning test is carried out, a thin layer of gold is sputtered on the surface of the optical fiber to prevent abnormal charging. It can be obviously observed that the nanofiber morphology is the same when the content of giant salamander powder in the system is different. The results are shown in FIG. 1.
As can be seen from fig. 1, dressing concentrations of 0%, 1%, 3%, 5% can form nanofibers to varying degrees. Whereas a dressing with a concentration of 7% does not form nanofibers. The appearance is the best is that the skin secretion concentration of giant salamander is 5%, and the spinning condition is selected to be 60kv, and the obtained nanofiber is the best. The fiber diameter was 375.+ -.30 nm.
Example 2
Preparing polylactic acid electrostatic spinning solution: dissolving polylactic acid in V Chloroform (chloroform) :V Dimethylformamide =7: 3, heating and magnetically stirring the mixed solution at 80 ℃ for 5 hours to obtain polylactic acid electrostatic spinning solution with the mass concentration of 10%; the electrostatic spinning was performed under the spinning conditions in example 1 (spinning voltage: 60 kv) to prepare a polylactic acid nanofiber membrane (PLA) having a fiber diameter of 375±30nm.
Meanwhile, a part of GS prepared at a spinning voltage of 60kv of the mixed spinning solution of the gelatin giant salamander with the concentration of 5% in example 1 was crosslinked. Specific: and (3) performing airtight crosslinking treatment by using glutaraldehyde steam with the volume concentration of 50% to enhance the mechanical property and reduce the solubility, and placing the crosslinked polylactic acid nanofiber membrane and gelatin giant salamander mixed nanofiber membrane in a vacuum drying oven at 40 ℃ for standing and drying for 3d to remove the influence of glutaraldehyde and acetic acid solvent. The crosslinked gelatin giant salamander mixed nanofiber membrane (GS (c)) is obtained.
According to the hot pressing method shown in fig. 1, with PLA as the bottom layer, sequentially superposing GS (c) and GS, and hot pressing PLA, GS (c) and GS at 100deg.C under 0.5MPa to obtain asymmetric nanofiber membrane (PGSGS) containing skin secretion of giant salamander (shown in fig. 2).
Example 3
Elastic tensile tests were performed on GS prepared in example 1 and PLA, GS (c), PGSGS prepared in example 2, and GS (c) GS composite films without PLA bottom layer.
In order to ensure the uniformity of the test results, the above samples were all subjected to a hot press treatment (100 ℃ C., 0.5 MPa) before the mechanical property test was performed. The test results are shown in FIG. 3.
As can be seen from fig. 3, the composition of PLA significantly improves the mechanical properties of GS or GS (c) and its composite film, which are originally poor in mechanical properties. This is critical for application in the actual wound repair process. And it can also be observed from fig. 3 that the mechanical properties of the composite film PGSGS are also significantly higher than those of PLA. The composite film better retains the mechanical properties of PLA.
Example 4
Adhesion performance test on PGSGS prepared in example 2
Pigskin is selected for adhesion testing, and PGSGS is adhered to the surface of pigskin for adhesion testing. The nanofiber membrane is adhered to the surface of pigskin tissue, the adhesion area is 10mm multiplied by 10mm, and the measurement is carried out by two modes of cutting and stretching respectively. As shown in FIG. 4, the adhesive strength at room temperature (26 ℃ C.) was 20KPa, and after standing at 4 ℃ C. For 20s, the adhesive strength was reduced to 4KPa, and the pig skin surface was easily removed. The characteristic enables the PGSGS auxiliary material to be easily removed from the wound by adopting a low-temperature treatment mode at 4 ℃ without causing secondary injury to the wound.
Example 5
The PLA and GS (c) were each subjected to contact angle testing, and the PLA and GS (c) were each adhered to a slide glass using a droplet shape analyzer device and placed on a stage. A drop of PBS solution was dropped on the sample with a syringe, and the solubility was observed. As a result, it was found that the PLA layer was hydrophobic, while the GS layer was hydrophilic, and the GS droplets dissolved in a very short time. After GS cross-linking (GS 5 means GS (c)) swelling behavior, PBS was absorbed but not dissolved.
In the use process, after the GS layer is dissolved, the swelling behavior of the GS (c) layer can enable the adhesion of the system to be maintained, because after the GS (c) layer is crosslinked, the GS (c) layer cannot be dissolved because the internal molecular chains are crosslinked, and at the moment, the adhesion strength is higher because the molecular chains are spread, so that the adhesion of the system is maintained. After low-temperature treatment, the gelatin chain can shrink, so that the molecular chains of the gelatin giant salamander are gathered, the adhesive strength of the gelatin giant salamander contacted with a tissue interface is reduced, and the gelatin giant salamander is easy to take down. As shown in fig. 5.
Example 6
In vitro biocompatibility experiments
Mouse 3T3 fibroblasts were cultured in DMEM (Hyclone, USA) supplemented with 5% fetal bovine serum. Gel (gelatin) (gelatin nanofiber, nanofiber obtained by electrostatic spinning of 20% gelatin spinning solution, solvent acetic acid)), GS (c) and PLA were weighed respectively with equal mass (5 mg). Sterilizing with ultraviolet rays for 30 minutes, soaking in DMEM for 3 days, and then co-culturing with cells in a 96-well plate for 24 hours, wherein since PLA and GS (c) are insoluble, they are spread on the cells, GS and Gel are dissolved, and their lysates are co-cultured with the cells. The CCK-8 method determines cell viability. The effect of various fibrous membrane materials on cells was observed (cell culture alone served as a blank). The statistical results are shown in fig. 6. As a result, the raw materials used in the invention have good biocompatibility, and cytotoxicity meets the conditions, and the invention belongs to the category of green wound dressings.
Mouse 3T3 fibroblasts were seeded on nanofiber membranes (PGSGS and GS) and blank plates (as controls) for 24 hours and then adherent cells were fixed with 4% paraformaldehyde. Cell morphology was observed by staining for cellular actin. The living/dead state of the cells was photographed using a laser scanning confocal microscope (OLYMPUS FV1000, japan), wherein black represents cell death, and after the dead staining was changed, if cell death occurred, red color appeared and cell survival was green. Grey figures are another method of imaging when cells survive. As can be seen from FIG. 7, GS and PGSGS have proliferation effects on cells.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (9)
1. The preparation method of the asymmetric nanofiber membrane containing giant salamander skin secretion is characterized by comprising the following steps of:
(1) Preparing a polylactic acid electrostatic spinning solution and a gelatin giant salamander mixed spinning solution;
(2) Respectively carrying out electrostatic spinning on the polylactic acid electrostatic spinning solution and the gelatin giant salamander mixed spinning solution to prepare a polylactic acid nanofiber membrane and a gelatin giant salamander mixed nanofiber membrane;
(3) Crosslinking a part of gelatin giant salamander mixed nanofiber membrane to obtain a crosslinked gelatin giant salamander mixed nanofiber membrane;
(4) And sequentially superposing and hot-pressing the gelatin giant salamander mixed nanofiber membrane, the crosslinked gelatin giant salamander mixed nanofiber membrane and the polylactic acid nanofiber membrane to obtain the asymmetric nanofiber membrane containing skin secretion of the giant salamander.
2. The method of claim 1, wherein the method for preparing the polylactic acid electrospinning solution of step (1) comprises the steps of: dissolving polylactic acid in V Chloroform (chloroform) :V Dimethylformamide =6 to 8: and 2-4 to obtain the polylactic acid electrostatic spinning solution with the mass concentration of 5-15%.
3. The method of claim 2, wherein the gelatin giant salamander mixed dope of step (1) is: dissolving giant salamander skin secretion in a gelatin glacial acetic acid solution with the mass volume concentration of 15-25% to obtain a gelatin giant salamander mixed spinning solution with the volume concentration of 1-5%.
4. The method according to claim 3, wherein the electrospinning in the step (2) is performed by using a syringe of 12-18 mL, the voltage is 50-70 kv, the solution flow rate is 0.8-2 mL/h, the needle receiver is a nonwoven fabric, the distance from the needle tip of the syringe to the receiver is 15-19 cm, the indoor temperature is 22-28 ℃ relative humidity is 40-60%, and the spinning time is 20-30 min.
5. The method of claim 4, wherein the diameter of the polylactic acid nanofiber membrane and the gelatin giant salamander mixed nanofiber membrane is 345-405 nm.
6. The method of claim 1, wherein the crosslinking in step (3) is performed using glutaraldehyde solution: the volume concentration of the glutaraldehyde solution is 45-55%.
7. The method of claim 1, wherein the hot pressing in step (4) is at a temperature of 90 to 110 ℃; the pressure of the hot pressing is 0.4-0.6 MPa.
8. An asymmetric nanofiber membrane containing skin secretions of giant salamanders obtained according to the preparation method of any one of claims 1 to 7.
9. Use of an asymmetric nanofiber membrane containing skin secretions of giant salamander according to claim 8 as a wound dressing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310588938.9A CN116607266A (en) | 2023-05-24 | 2023-05-24 | Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310588938.9A CN116607266A (en) | 2023-05-24 | 2023-05-24 | Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116607266A true CN116607266A (en) | 2023-08-18 |
Family
ID=87681277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310588938.9A Pending CN116607266A (en) | 2023-05-24 | 2023-05-24 | Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116607266A (en) |
-
2023
- 2023-05-24 CN CN202310588938.9A patent/CN116607266A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6699287B2 (en) | Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix | |
TWI445555B (en) | Dressing comprising active components of centella asiatica and use of the same | |
CN110772661A (en) | Nontoxic environment-friendly solvent type double-layer nanofiber skin dressing and preparation method thereof | |
CN106860919A (en) | De- cell amnion of crosslinking and its preparation method and application | |
CN105339018A (en) | Tissue repair scaffold and preparation method and purpose thereof | |
CN103480042B (en) | Artificial dura mater spinalis, and preparation method and use method thereof | |
US20190216984A1 (en) | Vascularized full thickness tissue-engineered skin assembled by hydrogel, nanofibrous scaffolds and skin cell layers and preparation method thereof | |
CN107823692B (en) | Wound dressing composite nanofiber membrane and preparation method thereof | |
CN104248777A (en) | Tissue repair support and its preparation method and use | |
CN107185025A (en) | A kind of Chinese medicine nanometer spinning composite cellulosic membrane dressing, preparation method and applications | |
CN107519524A (en) | A kind of polycaprolactone/collagen/quaternary ammonium salt electrospun composite fibers film and preparation method thereof | |
CN109718392A (en) | Composite medical dressing and preparation method thereof | |
Liu et al. | A novel wound dressing composed of nonwoven fabric coated with chitosan and herbal extract membrane for wound healing | |
CN111793854B (en) | Hyaluronic acid fiber material and preparation method thereof | |
US20220031446A1 (en) | Artificial dermis repair material and preparation method therefor | |
CN106901866A (en) | Compound dural patch for preventing adhesion and preparation method thereof | |
CN117838931B (en) | Dry amniotic membrane for improving mechanical strength and preparation method thereof | |
CN116139323A (en) | Wound dressing for burns and scalds, preparation method and application thereof | |
CN113046917B (en) | Electrostatic spinning collagen membrane and preparation method thereof | |
WO2017069365A1 (en) | Artificial biomembrane using silk matrix and method of manufacturing the same | |
WO2024109777A1 (en) | Artificial skin stent, biological printing method, and method for culturing artificial skin | |
CN113908338A (en) | Preparation method of silk fibroin biological patch | |
CN115804867B (en) | Fibrotic type III collagen nanomembrane, preparation method and application thereof in skin regeneration | |
CN115845114B (en) | Nanofiber medical wound dressing and preparation method thereof | |
CN116607266A (en) | Asymmetric nanofiber membrane containing giant salamander skin secretion and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |